The first clinical trial of an MF59®-adjuvanted influenza vaccine (Novartis) was conducted
20 years ago in 1992. The product that emerged (Fluad®, Novartis) was licensed first in Italy …

MF59 is a safe and effective vaccine adjuvant which was originally approved to be included
in a licensed influenza vaccine to be used in the elderly in Europe in 1997. The MF59 …

The MF59 adjuvant has been included in a licensed influenza vaccine for a decade. Hence,
we have a significant amount of clinical data to establish its potency and safety. We can now …

In preclinical studies, MF59 adjuvant offered improved protection against influenza virus
challenge and significantly reduced the viral load in the lungs of challenged mice. In …

The need to enhance the immunogenicity of purified subunit antigens has prompted the
development of several new adjuvants. However, many of these new molecules have …

BACKGROUND: Adding adjuvants such as MF59® to influenza vaccines can enhance the
immune response. This analysis evaluated the safety profile of MF59-adjuvanted [(+) MF59] …

Over the last decade, advances in subunit vaccine technology, achieved in many cases with
recombinant DNA techniques, have created a dramatic increase in demand for vaccine …

MF59 is a well-established, safe and potent vaccine adjuvant that has been licensed for
more than 13 years for use in an influenza vaccine focused on elderly subjects (Fluad® …

The need to enhance the immunogenicity of purified subunit antigens has prompted the
development of new adjuvants. The adjuvant emulsion MF59™ has been tested in animals …

Adjuvants are included in vaccine formulations to enhance the immunogenicity and efficacy
of vaccines. MF59® is an oil-in-water emulsion adjuvant and licensed for use in pandemic …